Tag Archives: Desvenlafaxine

Minor Depression

Etiology and Pathophysiology Minor depression is only a proposed diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and there are no International Classification of Diseases codes to categorize it. The proposed diagnostic category for minor depression in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition describes a depressive disorder that… Read More »

Minor Depression: Serotonin-Norepinephrine Reuptake Inhibitors

Research and development efforts in depression are focusing on a wide variety of mechanisms; agents with the now-familiar mechanism of serotonin-norepinephrine reuptake inhibition make up only a small portion of development efforts. The most notable of these serotonin/norepinephrine reuptake inhibitors is Eli Lilly’s recently launched duloxetine. Duloxetine is the third serotonin/norepinephrine reuptake inhibitor to market,… Read More »

Chronic Illness: Emerging Therapies

Few new drugs are in clinical development for the treatment of Bipolar disorder. Most agents in clinical trials for this disorder (e.g., Bristol-Myers Squibb’s aripiprazole, Novartis’s oxcarbazepine, AstraZeneca’s quetiapine, Janssen’s risperidone, Ortho-McNeil’s topiramate, Pfizer’s ziprasidone) are already available in the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) for the treatment… Read More »

Depression and Menopause

Prevalence Controversy over the existence of ‘involutional melancholia’ has spanned several centuries. More recently, the influence of estrogen on serotonin (5HT) receptors has been a topic of growing interest. There is also evidence that depressive symptoms increase around the perimenopause. Approximately 30% of women in this age group endorse symptoms associated with major depression or… Read More »

Second and third generation antidepressants

Selective Serotonin Reuptake Inhibitors Serotonin and norepinephrine reuptake inhibitor (SNRI) and other antidepressants Venlafaxine, milnacipran and duloxetine all inhibit both 5HT and norepinephrine reuptake, albeit in different ratios. Venlafaxine more potently inhibits the 5HT transporter, milnacaprin has more norepinephrine inhibiting effects and duloxetine appears to provide a more balanced dual inhibition. Desvenlafaxine succinate (DVS), an… Read More »